Post Test: Non-Small Cell Lung Cancer: Clinical and Economic Considerations in Targeting Therapy Based on Molecular Profiling

Published Online: January 01, 2014
Instructions

After reading “Non-Small Cell Lung Cancer: Clinical and Economic Considerations in Targeting Therapy Based on Molecular Profiling,” complete the program evaluation and select the single best answer to each of the posttest questions.

A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.




Take Physician CME Test

Take Pharmacist CE Test

PDF
Feature
Recommended Articles
Research conducted at the Duke University School of Medicine indicates triple therapy may increase risk of bleeding in geriatric patients with myocardial infarction who have a stent.
A research team at the Barts Cancer Institute in London has identified a 3-protein molecular signature in pancreatic cancer patients.
A study published in the American Journal of Preventive Medicine shows that grip strength of young, healthy adults could prove useful in the diagnosis of diabetes and hypertension.
The discovery could lead to targeted therapy in triple negative breast cancer patients.
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.